[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters to the Editor
December 2000

Are Glycine Sites Saturated In Vivo?

Arch Gen Psychiatry. 2000;57(12):1181-1183. doi:

In the January 1999 issue of the ARCHIVES, Farber et al1 commented on 2 recent clinical trials of glycinergic agents used to treat schizophrenia. The commentary, overall, supported the concept that underactivity of N-methyl-D-aspartate (NMDA) receptor–mediated neurotransmission may play a crucial role in the pathophysiology of schizophrenia. However, we feel it is important to discuss 3 specific issues raised in that commentary.

First Page Preview View Large
First page PDF preview
First page PDF preview
×